2020 Fiscal Year Final Research Report
Attempt of the T cell restoration of youth by metabolic control using metformin. Overcoming a limit of the TIL therapy.
Project/Area Number |
19K22362
|
Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
Allocation Type | Multi-year Fund |
Review Section |
Medium-sized Section 42:Veterinary medical science, animal science, and related fields
|
Research Institution | The University of Tokyo |
Principal Investigator |
Nakagawa Takayuki 東京大学, 大学院農学生命科学研究科(農学部), 准教授 (40447363)
|
Project Period (FY) |
2019-06-28 – 2021-03-31
|
Keywords | 犬 / 固形腫瘍 / 腫瘍免疫 / T細胞 / 代謝 |
Outline of Final Research Achievements |
Antitumor T cells that recognize tumor cells are exist in solid tumor tissue, but various factors suppress T cell function and inhibit antitumor response. In this study, we focused on an amino acid-metabolizing enzyme called IDO, which is overexpressed by tumor cells and immune cells, and examined the antitumor effect of IDO blocking therapy. As a result, it was found that high expression of IDO was observed in canine bladder cancer cells and tumor infiltrating immune cells, and that the antitumor response of canine T cells was enhanced by IDO inhibitors. As a further study, the IDO blocking therapy will be developed based on the results of this research.
|
Free Research Field |
獣医学
|
Academic Significance and Societal Importance of the Research Achievements |
悪性腫瘍は、犬・猫・人において主要な死亡原因であり、その克服は社会的な重要課題である。近年、抗腫瘍T細胞の増強による腫瘍免疫療法が明確な臨床効果を認め、新たな腫瘍治療法として期待されている。本研究では、IDO阻害薬により犬T細胞および犬固形腫瘍細胞の代謝を是正することで、抗腫瘍T細胞応答を増強できることを実証し、腫瘍免疫学分野における発展に貢献した。また、本研究では、犬腫瘍細胞株や犬T細胞を用いており、臨床応用性が高いことから臨床獣医学における新たな腫瘍治療法の基盤となる重要な成果を報告できた。
|